BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, Guest G, Boudailliez B, Bouissou F, Deschenes G, Gie S, Tsimaratos M, Fischbach M, Morin D, Nivet H, Alberti C, Loirat C; French Society of Pediatric Nephrology. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J Am Soc Nephrol. 2007;18:2392-2400. [PMID: 17599974 DOI: 10.1681/asn.2006080811] [Cited by in Crossref: 272] [Cited by in F6Publishing: 121] [Article Influence: 18.1] [Reference Citation Analysis]
Number Citing Articles
1 Salmon JE, Heuser C, Triebwasser M, Liszewski MK, Kavanagh D, Roumenina L, Branch DW, Goodship T, Fremeaux-Bacchi V, Atkinson JP. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 2011;8:e1001013. [PMID: 21445332 DOI: 10.1371/journal.pmed.1001013] [Cited by in Crossref: 195] [Cited by in F6Publishing: 174] [Article Influence: 17.7] [Reference Citation Analysis]
2 Bajracharya P, Jain A, Baracco R, Mattoo TK, Kapur G. Atypical hemolytic uremic syndrome: a clinical conundrum. Pediatr Nephrol 2016;31:1615-24. [PMID: 27139899 DOI: 10.1007/s00467-016-3369-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
3 Zuber J, Le Quintrec M, Sberro-soussan R, Loirat C, Frémeaux-bacchi V, Legendre C. New insights into postrenal transplant hemolytic uremic syndrome. Nat Rev Nephrol 2011;7:23-35. [DOI: 10.1038/nrneph.2010.155] [Cited by in Crossref: 124] [Cited by in F6Publishing: 92] [Article Influence: 10.3] [Reference Citation Analysis]
4 Raufi AG, Scott S, Darwish O, Harley K, Kahlon K, Desai S, Lu Y, Tran MH. Atypical Hemolytic Uremic Syndrome Secondary to Lupus Nephritis, Responsive to Eculizumab. Hematol Rep 2016;8:6625. [PMID: 27781079 DOI: 10.4081/hr.2016.6625] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
5 Seddon JM, Yu Y, Miller EC, Reynolds R, Tan PL, Gowrisankar S, Goldstein JI, Triebwasser M, Anderson HE, Zerbib J, Kavanagh D, Souied E, Katsanis N, Daly MJ, Atkinson JP, Raychaudhuri S. Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration. Nat Genet 2013;45:1366-70. [PMID: 24036952 DOI: 10.1038/ng.2741] [Cited by in Crossref: 198] [Cited by in F6Publishing: 187] [Article Influence: 22.0] [Reference Citation Analysis]
6 Kemmner S, Verbeek M, Heemann U. Renal dysfunction following bone marrow transplantation. J Nephrol 2017;30:201-9. [PMID: 27589851 DOI: 10.1007/s40620-016-0345-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
7 Lemaire M, Frémeaux-Bacchi V, Schaefer F, Choi M, Tang WH, Le Quintrec M, Fakhouri F, Taque S, Nobili F, Martinez F. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat Genet. 2013;45:531-536. [PMID: 23542698 DOI: 10.1038/ng.2590] [Cited by in Crossref: 317] [Cited by in F6Publishing: 261] [Article Influence: 35.2] [Reference Citation Analysis]
8 Jayasinghe K, Quinlan C, Stark Z, Patel C, Mallawaarachchi A, Wardrop L, Kerr PG, Trnka P, Mallett AJ; KidGen Collaborative. Renal genetics in Australia: Kidney medicine in the genomic age. Nephrology (Carlton) 2019;24:279-86. [PMID: 30239064 DOI: 10.1111/nep.13494] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
9 de Boer ECW, van Mourik AG, Jongerius I. Therapeutic Lessons to be Learned From the Role of Complement Regulators as Double-Edged Sword in Health and Disease. Front Immunol 2020;11:578069. [PMID: 33362763 DOI: 10.3389/fimmu.2020.578069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Salvadori M, Tsalouchos A. Therapeutic apheresis in kidney transplantation: An updated review. World J Transplant 2019; 9(6): 103-122 [PMID: 31750088 DOI: 10.5500/wjt.v9.i6.103] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
11 Alasfar S, Alachkar N. Atypical hemolytic uremic syndrome post-kidney transplantation: two case reports and review of the literature. Front Med (Lausanne) 2014;1:52. [PMID: 25593925 DOI: 10.3389/fmed.2014.00052] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
12 Greenwood GT. Case report of atypical hemolytic uremic syndrome with retinal arterial and venous occlusion treated with eculizumab. Int Med Case Rep J 2015;8:235-9. [PMID: 26508891 DOI: 10.2147/IMCRJ.S90640] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
13 Mache CJ, Acham-Roschitz B, Frémeaux-Bacchi V, Kirschfink M, Zipfel PF, Roedl S, Vester U, Ring E. Complement inhibitor eculizumab in atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009;4:1312-6. [PMID: 19556379 DOI: 10.2215/CJN.01090209] [Cited by in Crossref: 113] [Cited by in F6Publishing: 49] [Article Influence: 8.7] [Reference Citation Analysis]
14 Frémeaux-Bacchi V, Sellier-Leclerc AL, Vieira-Martins P, Limou S, Kwon T, Lahoche A, Novo R, Llanas B, Nobili F, Roussey G, Cailliez M, Ulinski T, Deschênes G, Alberti C, Weill FX, Mariani P, Loirat C. Complement Gene Variants and Shiga Toxin-Producing Escherichia coli-Associated Hemolytic Uremic Syndrome: Retrospective Genetic and Clinical Study. Clin J Am Soc Nephrol 2019;14:364-77. [PMID: 30674459 DOI: 10.2215/CJN.05830518] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
15 Dragon-Durey MA, Sethi SK, Bagga A, Blanc C, Blouin J, Ranchin B, André JL, Takagi N, Cheong HI, Hari P, Le Quintrec M, Niaudet P, Loirat C, Fridman WH, Frémeaux-Bacchi V. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J Am Soc Nephrol 2010;21:2180-7. [PMID: 21051740 DOI: 10.1681/ASN.2010030315] [Cited by in Crossref: 172] [Cited by in F6Publishing: 77] [Article Influence: 14.3] [Reference Citation Analysis]
16 Brocklebank V, Wong EK, Fielding R, Goodship TH, Kavanagh D. Atypical haemolytic uraemic syndrome associated with a CD46 mutation triggered by Shigella flexneri.. Clin Kidney J 2014;7:286-8. [PMID: 24944786 DOI: 10.1093/ckj/sfu032] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
17 Fuchs A, Atkinson JP, Fremeaux-Bacchi V, Kemper C. CD46-induced human Treg enhance B-cell responses. Eur J Immunol 2009;39:3097-109. [PMID: 19784949 DOI: 10.1002/eji.200939392] [Cited by in Crossref: 37] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
18 Hofer J, Rosales A, Fischer C, Giner T. Extra-renal manifestations of complement-mediated thrombotic microangiopathies. Front Pediatr. 2014;2:97. [PMID: 25250305 DOI: 10.3389/fped.2014.00097] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 5.0] [Reference Citation Analysis]
19 Fujisawa M, Kato H, Yoshida Y, Usui T, Takata M, Fujimoto M, Wada H, Uchida Y, Kokame K, Matsumoto M, Fujimura Y, Miyata T, Nangaku M. Clinical characteristics and genetic backgrounds of Japanese patients with atypical hemolytic uremic syndrome. Clin Exp Nephrol 2018;22:1088-99. [PMID: 29511899 DOI: 10.1007/s10157-018-1549-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
20 Zuber J, Fakhouri F, Roumenina LT, Loirat C, Frémeaux-Bacchi V. Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies. Nat Rev Nephrol. 2012;8:643-657. [PMID: 23026949 DOI: 10.1038/nrneph.2012.214] [Cited by in Crossref: 349] [Cited by in F6Publishing: 291] [Article Influence: 34.9] [Reference Citation Analysis]
21 Levy AR, Chen P, Johnston K, Wang Y, Popoff E, Tomazos I. Quantifying the economic effects of ravulizumab versus eculizumab treatment in patients with atypical hemolytic uremic syndrome. J Med Econ 2022;:1-16. [PMID: 35020547 DOI: 10.1080/13696998.2022.2027706] [Reference Citation Analysis]
22 Bacchetta J, Cochat P. Primary disease recurrence—effects on paediatric renal transplantation outcomes. Nat Rev Nephrol 2015;11:371-84. [PMID: 25917555 DOI: 10.1038/nrneph.2015.54] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.4] [Reference Citation Analysis]
23 Ariceta G, Besbas N, Johnson S, Karpman D, Landau D, Licht C, Loirat C, Pecoraro C, Taylor CM, Van de Kar N, Vandewalle J, Zimmerhackl LB; European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009;24:687-96. [PMID: 18800230 DOI: 10.1007/s00467-008-0964-1] [Cited by in Crossref: 225] [Cited by in F6Publishing: 173] [Article Influence: 16.1] [Reference Citation Analysis]
24 Geerdink LM, Westra D, van Wijk JA, Dorresteijn EM, Lilien MR, Davin JC, Kömhoff M, Van Hoeck K, van der Vlugt A, van den Heuvel LP, van de Kar NC. Atypical hemolytic uremic syndrome in children: complement mutations and clinical characteristics. Pediatr Nephrol 2012;27:1283-91. [PMID: 22410797 DOI: 10.1007/s00467-012-2131-y] [Cited by in Crossref: 91] [Cited by in F6Publishing: 80] [Article Influence: 9.1] [Reference Citation Analysis]
25 Berger BE. Atypical hemolytic uremic syndrome: a syndrome in need of clarity. Clin Kidney J 2019;12:338-47. [PMID: 31198222 DOI: 10.1093/ckj/sfy066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
26 Afshar-Kharghan V. Atypical hemolytic uremic syndrome. Hematology Am Soc Hematol Educ Program 2016;2016:217-25. [PMID: 27913483 DOI: 10.1182/asheducation-2016.1.217] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 4.4] [Reference Citation Analysis]
27 Pérez-Calatayud ÁA, Briones-Garduño JC, Álvarez-Goris Mdel P, Sánchez Zamora R, Torres Aguilar AA, Mendoza-Mórales RE. [Atipical uremic hemolityc syndrome in pregnancy]. Cir Cir 2016;84:344-9. [PMID: 27004941 DOI: 10.1016/j.circir.2016.02.001] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Sadler JE. What's new in the diagnosis and pathophysiology of thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program 2015;2015:631-6. [PMID: 26637781 DOI: 10.1182/asheducation-2015.1.631] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 7.0] [Reference Citation Analysis]
29 Wijnsma KL, Duineveld C, Wetzels JFM, van de Kar NCAJ. Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. Pediatr Nephrol 2019;34:2261-77. [PMID: 30402748 DOI: 10.1007/s00467-018-4091-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
30 de Jong S, de Breuk A, Volokhina EB, Bakker B, Garanto A, Fauser S, Katti S, Hoyng CB, Lechanteur YTE, van den Heuvel LP, den Hollander AI. Systemic complement levels in patients with age-related macular degeneration carrying rare or low frequency variants in the CFH gene. Hum Mol Genet 2021:ddab256. [PMID: 34508573 DOI: 10.1093/hmg/ddab256] [Reference Citation Analysis]
31 Loirat C, Girma JP, Desconclois C, Coppo P, Veyradier A. Thrombotic thrombocytopenic purpura related to severe ADAMTS13 deficiency in children. Pediatr Nephrol 2009;24:19-29. [PMID: 18574602 DOI: 10.1007/s00467-008-0863-5] [Cited by in Crossref: 43] [Cited by in F6Publishing: 30] [Article Influence: 3.1] [Reference Citation Analysis]
32 Matsumoto T, Fan X, Ishikawa E, Ito M, Amano K, Toyoda H, Komada Y, Ohishi K, Katayama N, Yoshida Y, Matsumoto M, Fujimura Y, Ikejiri M, Wada H, Miyata T. Analysis of patients with atypical hemolytic uremic syndrome treated at the Mie University Hospital: concentration of C3 p.I1157T mutation. Int J Hematol 2014;100:437-42. [PMID: 25135378 DOI: 10.1007/s12185-014-1655-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 26] [Article Influence: 4.3] [Reference Citation Analysis]
33 Sallée M, Ismail K, Fakhouri F, Vacher-Coponat H, Moussi-Francés J, Frémaux-Bacchi V, Burtey S. Thrombocytopenia is not mandatory to diagnose haemolytic and uremic syndrome. BMC Nephrol 2013;14:3. [PMID: 23298275 DOI: 10.1186/1471-2369-14-3] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
34 Weitz M, Amon O, Bassler D, Koenigsrainer A, Nadalin S. Prophylactic eculizumab prior to kidney transplantation for atypical hemolytic uremic syndrome. Pediatr Nephrol. 2011;26:1325-1329. [PMID: 21556717 DOI: 10.1007/s00467-011-1879-9] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 7.2] [Reference Citation Analysis]
35 Bu F, Borsa NG, Jones MB, Takanami E, Nishimura C, Hauer JJ, Azaiez H, Black-Ziegelbein EA, Meyer NC, Kolbe DL, Li Y, Frees K, Schnieders MJ, Thomas C, Nester C, Smith RJ. High-Throughput Genetic Testing for Thrombotic Microangiopathies and C3 Glomerulopathies. J Am Soc Nephrol 2016;27:1245-53. [PMID: 26283675 DOI: 10.1681/ASN.2015040385] [Cited by in Crossref: 60] [Cited by in F6Publishing: 36] [Article Influence: 8.6] [Reference Citation Analysis]
36 Salvadori M, Bertoni E. Update on hemolytic uremic syndrome: Diagnostic and therapeutic recommendations. World J Nephrol 2013; 2(3): 56-76 [PMID: 24255888 DOI: 10.5527/wjn.v2.i3.56] [Cited by in CrossRef: 64] [Cited by in F6Publishing: 44] [Article Influence: 7.1] [Reference Citation Analysis]
37 Loirat C, Noris M, Fremeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008;23:1957-72. [PMID: 18594873 DOI: 10.1007/s00467-008-0872-4] [Cited by in Crossref: 135] [Cited by in F6Publishing: 109] [Article Influence: 9.6] [Reference Citation Analysis]
38 Chan MR, Thomas CP, Torrealba JR, Djamali A, Fernandez LA, Nishimura CJ, Smith RJ, Samaniego MD. Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient. Am J Kidney Dis. 2009;53:321-326. [PMID: 18805611 DOI: 10.1053/j.ajkd.2008.06.027] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
39 Habibi I, Sfar I, Ben Alaya W, Methlouthi J, Ayadi A, Brahim M, Blouin J, Dhagbouj R, Ben Rhomdhane T, Makhlouf M, Aouadi H, Ayed-Jendoubi S, Fremeaux-Bacchi V, Sfar T, Ben Abdallah T, Ayed K, Gorgi Y. Atypical hemolytic uremic syndrome and mutation analysis of factor H gene in two Tunisian families. Int J Nephrol Renovasc Dis 2010;3:85-92. [PMID: 21694933 DOI: 10.2147/ijnrd.s8373] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
40 Eyler SJ, Meyer NC, Zhang Y, Xiao X, Nester CM, Smith RJ. A novel hybrid CFHR1/CFH gene causes atypical hemolytic uremic syndrome. Pediatr Nephrol 2013;28:2221-5. [PMID: 23880784 DOI: 10.1007/s00467-013-2560-2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 3.4] [Reference Citation Analysis]
41 McCullough JW, Renner B, Thurman JM. The role of the complement system in acute kidney injury. Semin Nephrol 2013;33:543-56. [PMID: 24161039 DOI: 10.1016/j.semnephrol.2013.08.005] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 6.3] [Reference Citation Analysis]
42 Bu F, Borsa N, Gianluigi A, Smith RJ. Familial atypical hemolytic uremic syndrome: a review of its genetic and clinical aspects. Clin Dev Immunol 2012;2012:370426. [PMID: 23251215 DOI: 10.1155/2012/370426] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
43 Wen J, Wang W, Xu F, Sun J, Chen J, Ni X. C3 glomerulonephritis and thrombotic microangiopathy of renal allograft after pulmonary infection in a male with concomitant two complement factor I gene variations: a case report. BMC Nephrol 2018;19:148. [PMID: 29940891 DOI: 10.1186/s12882-018-0952-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
44 Lapeyraque AL, Wagner E, Phan V, Clermont MJ, Merouani A, Frémeaux-Bacchi V, Goodship TH, Robitaille P. Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations. Pediatr Nephrol 2008;23:1363-6. [PMID: 18425537 DOI: 10.1007/s00467-008-0803-4] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
45 Sartain SE, Turner NA, Moake JL. Brain microvascular endothelial cells exhibit lower activation of the alternative complement pathway than glomerular microvascular endothelial cells. J Biol Chem 2018;293:7195-208. [PMID: 29555686 DOI: 10.1074/jbc.RA118.002639] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 5.8] [Reference Citation Analysis]
46 Fakhouri F, Scully M, Ardissino G, Al-Dakkak I, Miller B, Rondeau E. Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis. J Nephrol 2021. [PMID: 33826112 DOI: 10.1007/s40620-021-01025-x] [Reference Citation Analysis]
47 Infante B, Rossini M, Leo S, Troise D, Netti GS, Ranieri E, Gesualdo L, Castellano G, Stallone G. Recurrent Glomerulonephritis after Renal Transplantation: The Clinical Problem. Int J Mol Sci 2020;21:E5954. [PMID: 32824988 DOI: 10.3390/ijms21175954] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Kavanagh D, Raman S, Sheerin NS. Management of hemolytic uremic syndrome. F1000Prime Rep 2014;6:119. [PMID: 25580273 DOI: 10.12703/P6-119] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
49 Mele C, Remuzzi G, Noris M. Hemolytic uremic syndrome. Semin Immunopathol 2014;36:399-420. [PMID: 24526222 DOI: 10.1007/s00281-014-0416-x] [Cited by in Crossref: 92] [Cited by in F6Publishing: 67] [Article Influence: 11.5] [Reference Citation Analysis]
50 Joseph A, Cointe A, Mariani Kurkdjian P, Rafat C, Hertig A. Shiga Toxin-Associated Hemolytic Uremic Syndrome: A Narrative Review. Toxins (Basel) 2020;12:E67. [PMID: 31973203 DOI: 10.3390/toxins12020067] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 16.0] [Reference Citation Analysis]
51 Mühlig AK, Keir LS, Abt JC, Heidelbach HS, Horton R, Welsh GI, Meyer-Schwesinger C, Licht C, Coward RJ, Fester L, Saleem MA, Oh J. Podocytes Produce and Secrete Functional Complement C3 and Complement Factor H. Front Immunol 2020;11:1833. [PMID: 32922395 DOI: 10.3389/fimmu.2020.01833] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
52 Jayasinghe K, Stark Z, Kerr PG, Gaff C, Martyn M, Whitlam J, Creighton B, Donaldson E, Hunter M, Jarmolowicz A, Johnstone L, Krzesinski E, Lunke S, Lynch E, Nicholls K, Patel C, Prawer Y, Ryan J, See EJ, Talbot A, Trainer A, Tytherleigh R, Valente G, Wallis M, Wardrop L, West KH, White SM, Wilkins E, Mallett AJ, Quinlan C. Clinical impact of genomic testing in patients with suspected monogenic kidney disease. Genet Med 2021;23:183-91. [PMID: 32939031 DOI: 10.1038/s41436-020-00963-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
53 Medeni SS, Namdaroglu S, Cetintepe T, Ozlu C, Tasli F, Adibelli ZH, Bilgir O, Tatar E. An adult case of atypical hemolytic uremic syndrome presented with posterior reversible encephalopathy syndrome: Successful response to late-onset eculizumab treatment. Hematol Rep 2018;10:7553. [PMID: 30344987 DOI: 10.4081/hr.2018.7553] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
54 Lhotta K, Janecke AR, Scheiring J, Petzlberger B, Giner T, Fally V, Würzner R, Zimmerhackl LB, Mayer G, Fremeaux-Bacchi V. A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol. 2009;4:1356-1362. [PMID: 19590060 DOI: 10.2215/cjn.06281208] [Cited by in Crossref: 35] [Cited by in F6Publishing: 23] [Article Influence: 2.7] [Reference Citation Analysis]
55 Johnson SA, Wong EK, Taylor CM. Making sense of the spectrum of glomerular disease associated with complement dysregulation. Pediatr Nephrol 2014;29:1883-94. [PMID: 23852337 DOI: 10.1007/s00467-013-2559-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
56 Antwi-Baffour S, Kyeremeh R, Adjei JK, Aryeh C, Kpentey G. The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activation. Auto Immun Highlights 2016;7:6. [PMID: 26935316 DOI: 10.1007/s13317-016-0078-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
57 Johnson S, Taylor CM. What's new in haemolytic uraemic syndrome? Eur J Pediatr 2008;167:965-71. [PMID: 18575887 DOI: 10.1007/s00431-008-0745-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
58 Davin JC, van de Kar NC. Advances and challenges in the management of complement-mediated thrombotic microangiopathies. Ther Adv Hematol 2015;6:171-85. [PMID: 26288712 DOI: 10.1177/2040620715577613] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
59 Schönermarck U, Ries W, Schröppel B, Pape L, Dunaj-Kazmierowska M, Burst V, Mitzner S, Basara N, Starck M, Schmidbauer D, Mellmann A, Dittmer R, Jeglitsch M, Haas CS. Relative incidence of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome in clinically suspected cases of thrombotic microangiopathy. Clin Kidney J 2020;13:208-16. [PMID: 32296526 DOI: 10.1093/ckj/sfz066] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
60 Ávila A, Vizcaíno B, Molina P, Gavela E, Perez-Ebri M, Pallardó L. Remission of aHUS neurological damage with eculizumab. Clin Kidney J 2015;8:232-6. [PMID: 25815183 DOI: 10.1093/ckj/sfu144] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
61 Geerlings MJ, de Jong EK, den Hollander AI. The complement system in age-related macular degeneration: A review of rare genetic variants and implications for personalized treatment. Mol Immunol 2017;84:65-76. [PMID: 27939104 DOI: 10.1016/j.molimm.2016.11.016] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 12.7] [Reference Citation Analysis]
62 Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844-1859. [PMID: 20595690 DOI: 10.2215/cjn.02210310] [Cited by in Crossref: 584] [Cited by in F6Publishing: 274] [Article Influence: 48.7] [Reference Citation Analysis]
63 Jayasinghe K, Stark Z, Patel C, Mallawaarachchi A, McCarthy H, Faull R, Chakera A, Sundaram M, Jose M, Kerr P, Wu Y, Wardrop L, Goranitis I, Best S, Martyn M, Quinlan C, Mallett AJ. Comprehensive evaluation of a prospective Australian patient cohort with suspected genetic kidney disease undergoing clinical genomic testing: a study protocol. BMJ Open 2019;9:e029541. [PMID: 31383705 DOI: 10.1136/bmjopen-2019-029541] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
64 Kim S, Park E, Min SI, Yi NJ, Ha J, Ha IS, Cheong HI, Kang HG. Kidney Transplantation in Patients with Atypical Hemolytic Uremic Syndrome due to Complement Factor H Deficiency: Impact of Liver Transplantation. J Korean Med Sci 2018;33:e4. [PMID: 29215813 DOI: 10.3346/jkms.2018.33.e4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
65 Fremeaux-Bacchi V. Treatment of atypical uraemic syndrome in the era of eculizumab. Clin Kidney J 2012;5:4-6. [PMID: 26069738 DOI: 10.1093/ckj/sfr177] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
66 Ahmed Ali EM, Abbakar NM, Abdel Raheem MB, Ellidir RA. Characteristics and outcome of hemolytic uremic syndrome in Sudanese children in a single Centre in Khartoum State. Sudan J Paediatr 2017;17:42-8. [PMID: 29545664 DOI: 10.24911/SJP.2017.2.5] [Reference Citation Analysis]
67 Becker JU. Current status of pediatric renal transplant pathology. Pediatr Nephrol 2017;32:425-37. [PMID: 27221522 DOI: 10.1007/s00467-016-3381-x] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
68 Yenerel MN. Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management. Turk J Haematol 2014;31:216-25. [PMID: 25319590 DOI: 10.4274/tjh.2013.0374] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
69 Lopes D, Gomes AM, Cunha C, Pinto CS, Fidalgo T, Fernandes JC. New combined CFH/MCP mutations and a rare clinical course in atypical haemolytic uraemic syndrome. Clin Kidney J 2015;8:695-7. [PMID: 26613026 DOI: 10.1093/ckj/sfv102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
70 Zhang K, Lu Y, Harley KT, Tran MH. Atypical Hemolytic Uremic Syndrome: A Brief Review. Hematol Rep 2017;9:7053. [PMID: 28626544 DOI: 10.4081/hr.2017.7053] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
71 Asif A, Nayer A, Haas CS. Atypical hemolytic uremic syndrome in the setting of complement-amplifying conditions: case reports and a review of the evidence for treatment with eculizumab. J Nephrol 2017;30:347-62. [PMID: 27848226 DOI: 10.1007/s40620-016-0357-7] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 7.2] [Reference Citation Analysis]
72 Shin HS, Nester CM, Dixon BP. Comorbidity of inflammatory bowel disease with atypical hemolytic uremic syndrome in pediatric patients. Clin Nephrol Case Stud 2019;7:35-40. [PMID: 31312592 DOI: 10.5414/CNCS109511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
73 Loirat C, Fakhouri F, Ariceta G, Besbas N, Bitzan M, Bjerre A, Coppo R, Emma F, Johnson S, Karpman D. An international consensus approach to the management of atypical hemolytic uremic syndrome in children. Pediatr Nephrol. 2016;31:15-39. [PMID: 25859752 DOI: 10.1007/s00467-015-3076-8] [Cited by in Crossref: 272] [Cited by in F6Publishing: 210] [Article Influence: 38.9] [Reference Citation Analysis]
74 Socié G, Caby-Tosi MP, Marantz JL, Cole A, Bedrosian CL, Gasteyger C, Mujeebuddin A, Hillmen P, Vande Walle J, Haller H. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol 2019;185:297-310. [PMID: 30768680 DOI: 10.1111/bjh.15790] [Cited by in Crossref: 62] [Cited by in F6Publishing: 56] [Article Influence: 20.7] [Reference Citation Analysis]
75 Dowen F, Wood K, Brown AL, Palfrey J, Kavanagh D, Brocklebank V. Rare genetic variants in Shiga toxin-associated haemolytic uraemic syndrome: genetic analysis prior to transplantation is essential. Clin Kidney J 2017;10:490-3. [PMID: 28852487 DOI: 10.1093/ckj/sfx030] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
76 Delmas Y, Bordes C, Loirat C, Frémeaux-Bacchi V, Combe C. Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice. Clin Kidney J 2013;6:243-4. [PMID: 26019860 DOI: 10.1093/ckj/sfs185] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]
77 De Vriese AS, Sethi S, Van Praet J, Nath KA, Fervenza FC. Kidney Disease Caused by Dysregulation of the Complement Alternative Pathway: An Etiologic Approach. J Am Soc Nephrol. 2015;26:2917-2929. [PMID: 26185203 DOI: 10.1681/asn.2015020184] [Cited by in Crossref: 53] [Cited by in F6Publishing: 27] [Article Influence: 7.6] [Reference Citation Analysis]
78 Lim WH, Shingde M, Wong G. Recurrent and de novo Glomerulonephritis After Kidney Transplantation. Front Immunol 2019;10:1944. [PMID: 31475005 DOI: 10.3389/fimmu.2019.01944] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
79 Kavanagh D, Pappworth IY, Anderson H, Hayes CM, Moore I, Hunze EM, Bennaceur K, Roversi P, Lea S, Strain L. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? Clin J Am Soc Nephrol. 2012;7:417-426. [PMID: 22223611 DOI: 10.2215/cjn.05750611] [Cited by in Crossref: 38] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
80 Carter CE, Benador NM. Therapeutic plasma exchange for the treatment of pediatric renal diseases in 2013. Pediatr Nephrol 2014;29:35-50. [PMID: 23812351 DOI: 10.1007/s00467-013-2479-7] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
81 Kavanagh D, Goodship T. Genetics and complement in atypical HUS. Pediatr Nephrol 2010;25:2431-42. [PMID: 20526633 DOI: 10.1007/s00467-010-1555-5] [Cited by in Crossref: 117] [Cited by in F6Publishing: 98] [Article Influence: 9.8] [Reference Citation Analysis]
82 Rafiq A, Tariq H, Abbas N, Shenoy R. Atypical hemolytic-uremic syndrome: a case report and literature review. Am J Case Rep 2015;16:109-14. [PMID: 25708146 DOI: 10.12659/AJCR.892907] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
83 Matsumoto T, Toyoda H, Amano K, Hirayama M, Ishikawa E, Fujimoto M, Ito M, Ohishi K, Katayama N, Yoshida Y, Matsumoto M, Kawamura N, Ikejiri M, Kawakami K, Miyata T, Wada H. Clinical Manifestation of Patients With Atypical Hemolytic Uremic Syndrome With the C3 p.I1157T Variation in the Kinki Region of Japan. Clin Appl Thromb Hemost 2018;24:1301-7. [PMID: 29695177 DOI: 10.1177/1076029618771750] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
84 Boyer O, Niaudet P. Hemolytic uremic syndrome: new developments in pathogenesis and treatment. Int J Nephrol 2011;2011:908407. [PMID: 21876803 DOI: 10.4061/2011/908407] [Cited by in Crossref: 31] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
85 Soudabeh H, Ebrahim K, Nakisa H, Akbar D, Rozita HS, Bamedi T. Evaluation of complement regulatory components in patients with atypical hemolytic uremic syndrome. Cent Eur J Immunol 2014;39:67-70. [PMID: 26155102 DOI: 10.5114/ceji.2014.42127] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
86 Boudhabhay I, Rabant M, Roumenina LT, Coupry LM, Poillerat V, Marchal A, Frémeaux-Bacchi V, El Karoui K, Monchi M, Pourcine F. Case Report: Adult Post-COVID-19 Multisystem Inflammatory Syndrome and Thrombotic Microangiopathy. Front Immunol 2021;12:680567. [PMID: 34248962 DOI: 10.3389/fimmu.2021.680567] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
87 Reddy SK, Jahan A, Chaturvedi S, Agarwal I. Plasma exchange for paediatric kidney disease-indications and outcomes: a single-centre experience. Clin Kidney J 2015;8:702-7. [PMID: 26613028 DOI: 10.1093/ckj/sfv084] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
88 Salvadori M, Bertoni E. Complement related kidney diseases: Recurrence after transplantation. World J Transplant 2016; 6(4): 632-645 [PMID: 28058212 DOI: 10.5500/wjt.v6.i4.632] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
89 Alrahmani L, Willrich MAV. The Complement Alternative Pathway and Preeclampsia. Curr Hypertens Rep 2018;20:40. [PMID: 29717384 DOI: 10.1007/s11906-018-0836-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
90 Canpolat N. Hemolytic uremic syndrome. Turk Pediatri Ars 2015;50:73-82. [PMID: 26265890 DOI: 10.5152/tpa.2015.2297] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
91 Matsukuma E, Imamura A, Iwata Y, Takeuchi T, Yoshida Y, Fujimura Y, Fan X, Miyata T, Kuwahara T. Postoperative atypical hemolytic uremic syndrome associated with complement c3 mutation. Case Rep Nephrol 2014;2014:784943. [PMID: 25431709 DOI: 10.1155/2014/784943] [Cited by in Crossref: 3] [Article Influence: 0.4] [Reference Citation Analysis]
92 Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaimé F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8:554-562. [PMID: 23307876 DOI: 10.2215/cjn.04760512] [Cited by in Crossref: 385] [Cited by in F6Publishing: 194] [Article Influence: 42.8] [Reference Citation Analysis]
93 Bahougne T, Olagne J, Munch M, Braun-Parvez L, Chenard MP, Frémeaux-Bacchi V, Caillard S, Baltzinger P, Greget M, Kessler L, Moulin B. Atypical hemolytic and uremic syndrome due to C3 mutation in pancreatic islet transplantation: a case report. BMC Nephrol 2020;21:405. [PMID: 32950058 DOI: 10.1186/s12882-020-02062-7] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
94 Raina R, Grewal MK, Radhakrishnan Y, Tatineni V, DeCoy M, Burke LL, Bagga A. Optimal management of atypical hemolytic uremic disease: challenges and solutions. Int J Nephrol Renovasc Dis 2019;12:183-204. [PMID: 31564951 DOI: 10.2147/IJNRD.S215370] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
95 Joseph C, Gattineni J. Complement disorders and hemolytic uremic syndrome. Curr Opin Pediatr 2013;25:209-15. [PMID: 23399570 DOI: 10.1097/MOP.0b013e32835df48a] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
96 McCoy N, Weaver DJ Jr. Hemolytic uremic syndrome with simultaneous Shiga toxin producing Escherichia coli and complement abnormalities. BMC Pediatr 2014;14:278. [PMID: 25373393 DOI: 10.1186/1471-2431-14-278] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
97 Barbour T, Johnson S, Cohney S, Hughes P. Thrombotic microangiopathy and associated renal disorders. Nephrol Dial Transplant. 2012;27:2673-2685. [PMID: 22802583 DOI: 10.1093/ndt/gfs279] [Cited by in Crossref: 121] [Cited by in F6Publishing: 93] [Article Influence: 12.1] [Reference Citation Analysis]
98 Fakhouri F, Roumenina L, Provot F, Sallée M, Caillard S, Couzi L, Essig M, Ribes D, Dragon-Durey MA, Bridoux F. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol. 2010;21:859-867. [PMID: 20203157 DOI: 10.1681/asn.2009070706] [Cited by in Crossref: 274] [Cited by in F6Publishing: 100] [Article Influence: 22.8] [Reference Citation Analysis]
99 Gaggl M, Aigner C, Csuka D, Szilágyi Á, Prohászka Z, Kain R, Haninger N, Knechtelsdorfer M, Sunder-Plassmann R, Sunder-Plassmann G, Schmidt A. Maternal and Fetal Outcomes of Pregnancies in Women with Atypical Hemolytic Uremic Syndrome. J Am Soc Nephrol 2018;29:1020-9. [PMID: 29282226 DOI: 10.1681/ASN.2016090995] [Cited by in Crossref: 28] [Cited by in F6Publishing: 19] [Article Influence: 5.6] [Reference Citation Analysis]
100 Sana G, Dragon-Durey MA, Charbit M, Bouchireb K, Rousset-Rouvière C, Bérard E, Salomon R, Frémeaux-Bacchi V, Niaudet P, Boyer O. Long-term remission of atypical HUS with anti-factor H antibodies after cyclophosphamide pulses. Pediatr Nephrol 2014;29:75-83. [PMID: 23868108 DOI: 10.1007/s00467-013-2558-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 3.2] [Reference Citation Analysis]
101 Wong EK, Goodship TH, Kavanagh D. Complement therapy in atypical haemolytic uraemic syndrome (aHUS). Mol Immunol 2013;56:199-212. [PMID: 23810412 DOI: 10.1016/j.molimm.2013.05.224] [Cited by in Crossref: 60] [Cited by in F6Publishing: 54] [Article Influence: 6.7] [Reference Citation Analysis]
102 Bruel A, Kavanagh D, Noris M, Delmas Y, Wong EKS, Bresin E, Provôt F, Brocklebank V, Mele C, Remuzzi G, Loirat C, Frémeaux-Bacchi V, Fakhouri F. Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Clin J Am Soc Nephrol 2017;12:1237-47. [PMID: 28596415 DOI: 10.2215/CJN.00280117] [Cited by in Crossref: 86] [Cited by in F6Publishing: 37] [Article Influence: 17.2] [Reference Citation Analysis]
103 Davin JC, Buter N, Groothoff J, van Wijk J, Bouts A, Strain L, Goodship T. Prophylactic plasma exchange in CD46-associated atypical haemolytic uremic syndrome. Pediatr Nephrol 2009;24:1757-60. [PMID: 19373492 DOI: 10.1007/s00467-009-1188-8] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
104 Caillaud C, Zaloszyc A, Licht C, Pichault V, Frémeaux-Bacchi V, Fischbach M. CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS). Pediatr Nephrol 2016;31:157-61. [PMID: 26399238 DOI: 10.1007/s00467-015-3207-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 1.9] [Reference Citation Analysis]
105 Knoop M, Haller H, Menne J. [Human genetics in atypical hemolytic uremic syndrome-its role in diagnosis and treatment]. Internist (Berl) 2018;59:799-804. [PMID: 29995248 DOI: 10.1007/s00108-018-0455-9] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
106 Michaux K, Bacchetta J, Javouhey E, Cochat P, Frémaux-Bacchi V, Sellier-Leclerc AL. Eculizumab in neonatal hemolytic uremic syndrome with homozygous factor H deficiency. Pediatr Nephrol 2014;29:2415-9. [PMID: 25149852 DOI: 10.1007/s00467-014-2933-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
107 Pabst WL, Neuhaus TJ, Nef S, Bresin E, Zingg-Schenk A, Spartà G. Successful long-term outcome after renal transplantation in a patient with atypical haemolytic uremic syndrome with combined membrane cofactor protein CD46 and complement factor I mutations. Pediatr Nephrol 2013;28:1141-4. [PMID: 23519521 DOI: 10.1007/s00467-013-2450-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
108 Kalambay J, Zaman R, Zaman M. Atypical Hemolytic Uremic Syndrome Presenting as Pre-eclampsia in a 24-year-old Woman with Chronic Kidney Disease: Pathogenesis and Genetics. Cureus 2018;10:e3358. [PMID: 30510868 DOI: 10.7759/cureus.3358] [Reference Citation Analysis]
109 Noris M, Remuzzi G. Thrombotic microangiopathy: what not to learn from a meta-analysis. Nat Rev Nephrol 2009;5:186-8. [PMID: 19322181 DOI: 10.1038/nrneph.2009.28] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
110 Muff-Luett M, Nester CM. The Genetics of Ultra-Rare Renal Disease. J Pediatr Genet 2016;5:33-42. [PMID: 27617140 DOI: 10.1055/s-0036-1572515] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
111 Waters AM, Licht C. aHUS caused by complement dysregulation: new therapies on the horizon. Pediatr Nephrol. 2011;26:41-57. [PMID: 20556434 DOI: 10.1007/s00467-010-1556-4] [Cited by in Crossref: 87] [Cited by in F6Publishing: 74] [Article Influence: 7.3] [Reference Citation Analysis]
112 Davin JC, Strain L, Goodship TH. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr Nephrol 2008;23:1517-21. [PMID: 18483746 DOI: 10.1007/s00467-008-0833-y] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.5] [Reference Citation Analysis]
113 Johnson S, Stojanovic J, Ariceta G, Bitzan M, Besbas N, Frieling M, Karpman D, Landau D, Langman C, Licht C, Pecoraro C, Riedl M, Siomou E, van de Kar N, Walle JV, Loirat C, Taylor CM. An audit analysis of a guideline for the investigation and initial therapy of diarrhea negative (atypical) hemolytic uremic syndrome. Pediatr Nephrol 2014;29:1967-78. [PMID: 24817340 DOI: 10.1007/s00467-014-2817-4] [Cited by in Crossref: 54] [Cited by in F6Publishing: 49] [Article Influence: 6.8] [Reference Citation Analysis]
114 Sethi SK, Marie-Agnes DD, Thaker N, Hari P, Bagga A. Hemolytic uremic syndrome due to homozygous factor H deficiency. Clin Exp Nephrol 2009;13:526-30. [PMID: 19568827 DOI: 10.1007/s10157-009-0205-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
115 Bresin E, Rurali E, Caprioli J, Sanchez-Corral P, Fremeaux-Bacchi V, Rodriguez de Cordoba S, Pinto S, Goodship TH, Alberti M, Ribes D. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J Am Soc Nephrol. 2013;24:475-486. [PMID: 23431077 DOI: 10.1681/asn.2012090884] [Cited by in Crossref: 231] [Cited by in F6Publishing: 110] [Article Influence: 25.7] [Reference Citation Analysis]
116 Bello-Marquez DC, Nieto-Rios JF, Serna-Higuita LM, Gonzalez-Vergara AJ. Nephrotic syndrome associated with primary atypical hemolytic uremic syndrome. J Bras Nefrol 2021;43:440-4. [PMID: 32779691 DOI: 10.1590/2175-8239-JBN-2020-0050] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
117 Tawadrous H, Maga T, Sharma J, Kupferman J, Smith RJ, Schoeneman M. A novel mutation in the complement factor B gene (CFB) and atypical hemolytic uremic syndrome. Pediatr Nephrol 2010;25:947-51. [PMID: 20108004 DOI: 10.1007/s00467-009-1415-3] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
118 Kavanagh D, Goodship TH, Richards A. Atypical hemolytic uremic syndrome. Semin Nephrol. 2013;33:508-530. [PMID: 24161037 DOI: 10.1016/j.semnephrol.2013.08.003] [Cited by in Crossref: 204] [Cited by in F6Publishing: 156] [Article Influence: 25.5] [Reference Citation Analysis]
119 Loirat C, Frémeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J Rare Dis 2011;6:60. [PMID: 21902819 DOI: 10.1186/1750-1172-6-60] [Cited by in Crossref: 375] [Cited by in F6Publishing: 304] [Article Influence: 34.1] [Reference Citation Analysis]
120 Ruebner RL, Kaplan BS, Copelovitch L. A time for reappraisal of "atypical" hemolytic uremic syndrome: should all patients be treated the same? Eur J Pediatr 2012;171:1519-25. [PMID: 22673930 DOI: 10.1007/s00431-012-1763-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
121 Al-Akash SI, Almond PS, Savell VH, Gharaybeh SI, Hogue C. Eculizumab induces long-term remission in recurrent post-transplant HUS associated with C3 gene mutation. Pediatr Nephrol. 2011;26:613-619. [PMID: 21125405 DOI: 10.1007/s00467-010-1708-6] [Cited by in Crossref: 76] [Cited by in F6Publishing: 67] [Article Influence: 6.3] [Reference Citation Analysis]
122 Hofer J, Janecke AR, Zimmerhackl LB, Riedl M, Rosales A, Giner T, Cortina G, Haindl CJ, Petzelberger B, Pawlik M, Jeller V, Vester U, Gadner B, van Husen M, Moritz ML, Würzner R, Jungraithmayr T; German-Austrian HUS Study Group. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin J Am Soc Nephrol 2013;8:407-15. [PMID: 23243267 DOI: 10.2215/CJN.01260212] [Cited by in Crossref: 80] [Cited by in F6Publishing: 34] [Article Influence: 8.0] [Reference Citation Analysis]
123 Cheng C, Chen L, Wen S, Lin Z, Jiang X. Case Report: Denys-Drash Syndrome With WT1 Causative Variant Presenting as Atypical Hemolytic Uremic Syndrome. Front Pediatr 2020;8:605889. [PMID: 33392118 DOI: 10.3389/fped.2020.605889] [Reference Citation Analysis]
124 Zwang NA, Ho B, Kanwar YS, Lewis B, Cusick M, Friedewald JJ, Gallon L. A case of atypical hemolytic uremic syndrome in a second renal transplant. J Nephrol 2018;31:165-72. [PMID: 28224376 DOI: 10.1007/s40620-016-0373-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
125 Cheong HI, Jo SK, Yoon SS, Cho H, Kim JS, Kim YO, Koo JR, Park Y, Park YS, Shin JI, Yoo KH, Oh D. Clinical Practice Guidelines for the Management of Atypical Hemolytic Uremic Syndrome in Korea. J Korean Med Sci 2016;31:1516-28. [PMID: 27550478 DOI: 10.3346/jkms.2016.31.10.1516] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
126 Fraga-Rodriguez GM, Brió-Sanagustin S, Turón-Viñas E, Dixon BP, Carreras-González E. Eculizumab in a child with atypical haemolytic uraemic syndrome and haemophagocytic lymphohistiocytosis triggered by cytomegalovirus infection. BMJ Case Rep 2017;2017:bcr-2016-219065. [PMID: 28446488 DOI: 10.1136/bcr-2016-219065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
127 Almalki AH, Sadagah LF, Qureshi M, Maghrabi H, Algain A, Alsaeed A. Atypical hemolytic-uremic syndrome due to complement factor I mutation. World J Nephrol 2017; 6(6): 243-250 [PMID: 29226095 DOI: 10.5527/wjn.v6.i6.243] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
128 Formeck C, Swiatecka-Urban A. Extra-renal manifestations of atypical hemolytic uremic syndrome. Pediatr Nephrol 2019;34:1337-48. [PMID: 30109445 DOI: 10.1007/s00467-018-4039-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
129 Yamada Y, Abe R, Okano Y, Miyakawa Y. Long-term Eculizumab Treatment Contributes to Recovery from End-stage Renal Disease Caused by Atypical Hemolytic Uremic Syndrome. Intern Med 2017;56:1085-8. [PMID: 28458317 DOI: 10.2169/internalmedicine.56.7862] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]